Intelence Demonstrates Continued Efficacy In HIV At 48-Weeks, Tibotec Reports
This article was originally published in The Pink Sheet Daily
Executive Summary
After accelerated approval last month, J&J affiliate is ready to complete its marketing application for the new NNRTI.
You may also be interested in...
“Creative” FDA Clears Avastin For First-Line Breast Cancer
Accelerated approval wants more clinical proof.
“Creative” FDA Clears Avastin For First-Line Breast Cancer
Accelerated approval wants more clinical proof.
J&J’s Intelence Approved For HIV Treatment In NNRTI-Resistant Patients
Johnson & Johnson’s Tibotec unit prices etravirine at wholesale acquisition cost of $5.45, firm tells “The Pink Sheet” DAILY.